Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer-Reference-Cited by-同舟云学术

Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer

Published:2021-09 Issue:3 Volume:162 Page:619-625
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Backes Floor J.,Wei Lai,Chen Min,Hill Kasey,Dzwigalski Kyle,Poi Ming,Phelps Mitch,Salani Ritu,Copeland Larry J.,Fowler Jeffrey M.,Cohn David E.,Bixel Kristin,Cosgrove Casey,Hays John,O'Malley David

Funder

Eisai Korea Inc

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference27 articles.

1. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase;Matsui;Clin. Cancer Res.,2008

2. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition;Matsui;Int. J. Cancer,2008

3. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes;Vergote;J. Clin. Oncol.,2013

4. Second-line lenvatinib in patients with recurrent endometrial cancer;Vergote;Gynecol. Oncol.,2020

5. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial;Makker;Lancet Oncol.,2019

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study;Gynecologic Oncology;2024-07

2. Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study;International Journal of Gynecologic Cancer;2024-04-24

3. Primary ovarian insufficiency associated with lenvatinib therapy in a patient with hepatocellular carcinoma: A case report;Oncology Letters;2023-08-31

4. Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy;Gynecologic Oncology Reports;2023-08

5. Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers;Biomedicines;2023-01-01